Imbruvica (ibrutinib)

Product Name:

Imbruvica (ibrutinib)

Categories: Hematology, Oncology

Discover Savings on Your Medication Access

Trusted concierge service, secure process, and real savings for patients in the U.S.

Table of Contents

Imbruvica (ibrutinib)

Product Category

Targeted Therapy – Bruton’s Tyrosine Kinase (BTK) Inhibitor

Brand Name

Imbruvica

Generic Name or Biosimilar

No generic equivalent available

Active Ingredient

Ibrutinib

Prescription Status

Prescription-only

Targeted Conditions

Imbruvica is FDA-approved to treat the following hematologic malignancies:

  • Chronic lymphocytic leukemia (CLL)
  • Small lymphocytic lymphoma (SLL)
  • Mantle cell lymphoma (MCL) – in patients who have received at least one prior therapy
  • Waldenström’s macroglobulinemia (WM)
  • Marginal zone lymphoma (MZL) – in patients who require systemic therapy and have received at least one prior anti-CD20-based therapy
  • Chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy

Off-Label Usage

  • Diffuse large B-cell lymphoma (DLBCL)
  • Follicular lymphoma (FL)
  • Multiple myeloma (MM)
  • Other investigational autoimmune and hematologic conditions as determined by a specialist

All off-label use must be under strict medical supervision.

Drug Classification Overview

Imbruvica is classified as a Bruton’s Tyrosine Kinase (BTK) inhibitor. By binding irreversibly to BTK, it blocks B-cell receptor signaling pathways, which are critical for the survival and proliferation of malignant B-cells. This targeted inhibition helps slow or stop the progression of B-cell cancers.

Manufacturer in the USA, Mexico, and Canada

  • USA: Pharmacyclics LLC (an AbbVie Company) and Janssen Biotech, Inc.
  • Canada: Janssen Inc.
  • Mexico: Janssen-Cilag S.A. de C.V.

Available Strengths and Dosage Forms – United States, Mexico, and Canada

Country Comparison – United States vs Mexico and Canada

  • Identical active ingredient (ibrutinib) across all countries
  • Packaging and labeling may differ by jurisdiction
  • Dosage strengths available may vary slightly based on regulatory approval
  • All supplied products meet international safety and efficacy standards

Average Retail Price (Monthly Treatment) USA vs Mexico vs Canada

  • 1
    Canada: Savings of approximately 30%–50% compared to U.S. retail prices
  • 2
    Mexico: Savings of approximately 35%–55% compared to U.S. retail prices

Prices vary depending on local regulations, prescription requirements, and distribution channels.

Where to Buy USA

Imbruvica is available by prescription from the following U.S. pharmacies:

  • CVS
  • Walgreens
  • Walmart
  • Costco
  • Rite Aid
  • Kroger
  • Albertsons
  • Sam’s Club
  • Publix
  • Target (via CVS)
  • Online specialty mail-order pharmacies

Access and pricing may vary depending on insurance coverage and pharmacy network.

Storage Requirements

  • Store at room temperature (20°C–25°C / 68°F–77°F).
  • Keep in original container with desiccant to protect from moisture.
  • Do not store in the bathroom.
  • Keep container tightly closed when not in use.

Shipping from Canada

This medication is dispensed through licensed Canadian pharmacies under the oversight of Health Canada. All pharmacies in the MedicalMex network are carefully vetted to ensure authenticity, safety, and compliance with Canadian regulations.

MedicalMex facilitates:

  • Prescription verification and fulfillment coordination
  • Secure, compliant medication logistics
  • Access to licensed Canadian pharmacists
  • Telehealth support through certified physicians if required
  • Case management, payment handling, and concierge-level support
  • Temperature-monitored cold chain shipping where required
  • Refill and adherence tracking programs

Buying from Mexico

Imbruvica can also be accessed via certified pharmacies in Mexico under the supervision of COFEPRIS. All partner pharmacies in the MedicalMex network are validated for safety and regulatory compliance.

MedicalMex facilitates:

  • Transportation assistance to our partner clinic in Tijuana, Mexico
  • Prescription management through licensed physicians in our network
  • Telehealth consultations with accredited providers if necessary
  • Travel coordination, including flights and hotel bookings
  • Travel insurance services
  • Cold chain logistics with advanced monitoring when applicable
  • Boutique-level personalized support
  • Ongoing refill and adherence assistance

Key Benefits

  • Oral administration (convenient daily pill)
  • Effective across multiple B-cell malignancies
  • Improved progression-free survival in CLL and MCL
  • Non-chemotherapy oral targeted therapy
  • Generally well-tolerated compared to traditional chemotherapy

Side Effects

Common Side Effects:

  • Diarrhea
  • Fatigue
  • Musculoskeletal pain
  • Bruising
  • Rash
  • Nausea

Serious Side Effects:

  • Serious infections (bacterial, viral, fungal)
  • Bleeding complications
  • Cardiac arrhythmias (atrial fibrillation, ventricular tachycardia)
  • Second primary malignancies (including skin cancers)
  • Hypertension (new or worsening)

Warnings and Precautions

  • Monitor for signs of bleeding, especially in patients on anticoagulants
  • Increased risk of infections – prophylaxis may be recommended in some cases
  • Cardiac monitoring advised in patients with history of arrhythmia
  • Monitor blood pressure regularly during treatment
  • Avoid live vaccines while on therapy
  • Pregnancy and breastfeeding should be avoided during and after treatment

Alternative Medications (by Indication)

  • Calquence (acalabrutinib)
  • Zydelig (idelalisib)
  • Venclexta (venetoclax)
  • Revlimid (lenalidomide)

Medication FAQs

Imbruvica is used to treat CLL, SLL, MCL, WM, MZL, and cGVHD by inhibiting BTK and blocking B-cell receptor signaling.

It is administered orally once daily in capsule or tablet form.

Treatment is typically continued until disease progression or unacceptable toxicity occurs.

No. It is a targeted oral therapy, not a traditional chemotherapy drug.

Yes. It may be combined with rituximab, obinutuzumab, or venetoclax depending on the indication.

Yes. Regular blood counts, blood pressure checks, and heart monitoring are recommended during therapy.

Yes. It is available through licensed pharmacies and regulated by Health Canada and COFEPRIS.

Yes. A valid prescription from a licensed physician is required to obtain Imbruvica in all countries.